Clinical Informatics

Startin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ing with the Encounter_Data.xlsx [A] (the data elements of a non-ophthalmologic encounter), isolate data elements relevant to glaucoma screenin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ing (Prum, Lim et al; p P120-122) that are missin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ing from [A] and add them to the appropriate sections in" rel="nofollow">in" rel="nofollow">in" rel="nofollow">in [A]. Again" rel="nofollow">in" rel="nofollow">in" rel="nofollow">in, keep in" rel="nofollow">in" rel="nofollow">in" rel="nofollow">in min" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ind that generalists will not be performin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ing ophthalmologic tests or examin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">inations other than basic visual-acuity testin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ing (therefore, these are NOT to be in" rel="nofollow">in" rel="nofollow">in" rel="nofollow">included in" rel="nofollow">in" rel="nofollow">in" rel="nofollow">in your modifications to [A]. Summarizin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ing: 1. Highlight those items that are already in" rel="nofollow">in" rel="nofollow">in" rel="nofollow">in [A] that are relevant to POAG screenin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ing (mark by changin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ing background color to yellow) 2. Add relevant items to [A] that are not ophthalmology-specific (ie. that require examin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ination by special ophthalmologic diagnostic tools) data items and highlight them (mark by changin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ing background color to green). 3. If there are specific rules that identify a value within" rel="nofollow">in" rel="nofollow">in" rel="nofollow">in a field that as a risk factor in" rel="nofollow">in" rel="nofollow">in" rel="nofollow">in screenin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ing, put the rule in" rel="nofollow">in" rel="nofollow">in" rel="nofollow">into the "Ruler column: a. Example: IF AGE GT 40, THEN b. NB: There is no "AGE" datum in" rel="nofollow">in" rel="nofollow">in" rel="nofollow">in the Encounter Form. How would this be addressed? (Use the DF if you are confused) Part 2: Answer the followin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ing questions: 1. What is the clin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">inical purpose of makin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ing the changes in" rel="nofollow">in" rel="nofollow">in" rel="nofollow">in [A]? 2. What are specific risk factors associated with POAG NOT related to ophthalmologic-specific measures or tests? 3. What are specific items that will be highlighted in" rel="nofollow">in" rel="nofollow">in" rel="nofollow">in [A] associated with POAG that are part of: a. History b. Physical Examin" rel="nofollow">in" rel="nofollow">in" rel="nofollow">ination 4. Given the discussion by Lim and Goldberg, what are other in" rel="nofollow">in" rel="nofollow">in" rel="nofollow">interventions that the collective practices can undertake to improve timely detection of glaucoma within" rel="nofollow">in" rel="nofollow">in" rel="nofollow">in their patient population/community and how might they implement these in" rel="nofollow">in" rel="nofollow">in" rel="nofollow">interventions?